JCEM:血液中胰多肽的浓度能够预测内脏及肝脏的脂肪含量

2014-12-30 MedSci MedSci原创

一项来自英国的研究表明血液中的胰多肽浓度能够预测内脏和肝脏的脂肪含量,能够作为一种新型的指标,对于心血管疾病的风险分级以及脂肪异位沉积患者的而治疗来说都具有潜在价值。预测内脏和肝脏脂肪含量的可靠生物指标迄今尚未被明确,这两种脂肪含量均是心血管疾病的危险因素。迷走神经兴奋被认为能够影响局部脂肪的分布,胰多肽是在迷走神经的调控下由胰腺分泌的。我们研究胰多肽在预测内脏和肝脏脂肪中的作用。 研究纳入了1

一项来自英国的研究表明血液中的胰多肽浓度能够预测内脏和肝脏的脂肪含量,能够作为一种新型的指标,对于心血管疾病的风险分级以及脂肪异位沉积患者的而治疗来说都具有潜在价值。
预测内脏和肝脏脂肪含量的可靠生物指标迄今尚未被明确,这两种脂肪含量均是心血管疾病的危险因素。迷走神经兴奋被认为能够影响局部脂肪的分布,胰多肽是在迷走神经的调控下由胰腺分泌的。我们研究胰多肽在预测内脏和肝脏脂肪中的作用。

研究纳入了104名超重和肥胖患者(46名男性和58名女性),并测量他们空腹血浆中的胰多肽浓度。同样地,通过全身的磁共振成像(MRI)对他们的总脂肪和局部脂肪含量进行了了测量,包括总内脏脂肪组织(VAT))及总皮下脂肪组织(TSAT)。肝细胞内的脂肪含量(IHCL)通过质子磁共振波谱分析来确定。

血浆中胰多肽的浓度与内脏脂肪组织(VAT))(r=0.57, p<0.001)及肝细胞内的脂肪含量(IHCL)((r=0.51, p <0.001))成正相关,但与总的皮下脂肪组织(TSAT) (r=0.02, p=0.88)无关。在对患者的年龄和性别进行校正后,空腹血浆中的胰多肽浓度能够独立预测VAT。在对患者的年龄、性别、BMI、WHR、HOMA2-IR及血浆中甘油三酯、总胆固醇及丙氨酸转氨酶进行校正后,空腹血浆中的胰多肽浓度能够独立预测IHCL。空腹血浆胰多肽浓度与血浆中丙氨酸转氨酶、总胆固醇、甘油三酯、低密度脂蛋白和高密度脂蛋白及血压有关(p<0.05)。这种关联式有IHCL和/或VAT介导的。空腹血浆的胰多肽和HOMA2-IR分别与肝脏的脂肪变相关(p<0.01)。

胰多肽是一种新型的预测内脏和肝脏脂肪含量的指标,因此对于心血管疾病的风险分级以及脂肪异位沉积患者的而治疗来说都是一个具有潜在价值的生物指标。

原始出处

Sam AH1, Sleeth ML, Thomas EL.et.al.Circulating pancreatic polypeptide concentrations predict visceral and liver fat content.J Clin Endocrinol Metab. 2014 Dec 9

本文是MedSci编译,转载需注明出处,非常感谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1777504, encodeId=cec01e77504bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jun 23 19:02:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062886, encodeId=6c97206288667, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Nov 20 20:02:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17549, encodeId=96571e54928, content=超赞,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:46:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530030, encodeId=bba9153003021, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544394, encodeId=f2151544394c9, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=)]
    2015-06-23 smallant2015
  2. [GetPortalCommentsPageByObjectIdResponse(id=1777504, encodeId=cec01e77504bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jun 23 19:02:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062886, encodeId=6c97206288667, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Nov 20 20:02:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17549, encodeId=96571e54928, content=超赞,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:46:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530030, encodeId=bba9153003021, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544394, encodeId=f2151544394c9, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=)]
    2015-11-20 achengzhao
  3. [GetPortalCommentsPageByObjectIdResponse(id=1777504, encodeId=cec01e77504bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jun 23 19:02:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062886, encodeId=6c97206288667, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Nov 20 20:02:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17549, encodeId=96571e54928, content=超赞,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:46:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530030, encodeId=bba9153003021, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544394, encodeId=f2151544394c9, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=)]
    2015-03-04 xiaoai5777

    超赞,好文章

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1777504, encodeId=cec01e77504bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jun 23 19:02:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062886, encodeId=6c97206288667, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Nov 20 20:02:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17549, encodeId=96571e54928, content=超赞,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:46:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530030, encodeId=bba9153003021, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544394, encodeId=f2151544394c9, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=)]
    2015-01-01 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=1777504, encodeId=cec01e77504bf, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Jun 23 19:02:00 CST 2015, time=2015-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062886, encodeId=6c97206288667, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Fri Nov 20 20:02:00 CST 2015, time=2015-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17549, encodeId=96571e54928, content=超赞,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:46:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530030, encodeId=bba9153003021, content=<a href='/topic/show?id=fd6f4340017' target=_blank style='color:#2F92EE;'>#多肽#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43400, encryptionId=fd6f4340017, topicName=多肽)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdb812012363, createdName=fusion, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544394, encodeId=f2151544394c9, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Thu Jan 01 06:02:00 CST 2015, time=2015-01-01, status=1, ipAttribution=)]

相关资讯

欧盟批准阿斯利康易瑞沙(Iressa)血液ctDNA伴随诊断

阿斯利康(AstraZeneca)肿瘤学药物易瑞沙(Iressa,通用名:gefitinib,吉非替尼)近日获得了欧盟的好消息。欧洲药品管理局(EMA)人用医药产品委员会(CHMP)已建议批准Iressa标签II型变化更新,该标签更新,将使医生能够采用血液循环肿瘤细胞DNA(ctDNA)检测方法,评估EGFR突变状态,进而鉴别出最可能从Iressa治疗中受益的非小细胞肺癌(NSCLC)患者群体

JASN:自身免疫性疾病复发可通过血液预测

自身免疫疾病往往累及到患者自身的肾脏,监测患者血液中的一种自身抗体可帮助医生预测疾病复发的风险。 结果发表在Journal of the American Society of Nephrology (JASN)杂志上。这一措施可能有助于保护患者的肾脏健康。 自身免疫性病症(抗中性粒细胞胞浆抗体ANCA相关性血管炎)患者,体内产生抗体损伤体内血管。病症的复发可能导致器官和身体的其它部位发生

携带黄金血液的男子

生驾驶汽车带着他穿过边界。这是捐血的最快捷方法,因为他如果在瑞士捐血,血液会被文书工作耽搁。 这名叫Thomas的男子拥有着非同寻常的血型,研究人员在50年里只发现大约40个人携带这种罕见的血型。红血细胞将氧气输送到人体内的其它细胞和组织,如果在手术或事故中失去了大量血,我们需要快速获得输血。但输血必须匹配血型。虽然每个人都有红血细胞,但红血细胞中的抗原存在差异,我们有最多342种抗原,特

全基因组测序时代:我们应该探知胎儿的未来吗?

  一项新技术或产品的问世,在给人们带来欣喜的同时,也可能引起担忧。 国际权威刊物《自然》杂志曾发表一篇报道,称仅利用怀孕妇女的血液样本就能获得胎儿的DNA,从而进行胎儿的基因组测序。这项研究提示,妊娠早期即可对胎儿进行全基因组测序,这一技术使得产前检查又提高到新的水平。 有了上述新方法之后,准父母可以获得孩子的基因信息,不仅可以预测孩子儿童时期的疾病,还能得知孩子是否携带常

Nature:挑战教科书,揭示血液真实起源

一个为期7年的研究项目开发出了一种组织干细胞条码和追踪系统,揭示出了从前未被了解的有关正常血液生成的一些特征:来自波士顿儿童医院哈佛干细胞研究所科学家们的新数据表明,出人意料,我们每天生成的数十亿血细胞并非是由造血干细胞,而是少一些多能性的后代细胞——祖细胞所产生。研究人员猜测,血液源自于不同的稳定长寿祖细胞群,它们负责生成了特定的血细胞类型,而造血干细胞有可能是充当了至关重要的储备库。这项获得美

Clin Gastroenterol Hepatol:大肠癌筛查的新血液生物标志物

在搜寻可以用于筛查大肠癌(CRC)的血源性生物标志物过程中,研究人员发现两个有前途的候选标志物有望用于开发新的血液测试。 科学家们一直在探究参与CRC发展的分子机制,并且已确定异常的DNA甲基化模式和microRNAs的存在是大肠癌发生发展过程的主要参与者。在22nd United European Gastroenterology Week (UEG Week 2014)上,西班牙巴塞罗那消